公开(公告)号：US20190316087A1

公开(公告)日：2019-10-17

申请号：US16313486

申请日：2017-06-27

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER ,  Noga OR-GEVA ,  Rotem GIDRON BUDOVSKY ,  Esther BACHAR-LUSTIG ,  Assaf LASK ,  Sivan KAGAN

IPC: C12N5/0783 ,  C12N5/00 ,  A61K35/17 ,  A61K39/00

Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.

公开(公告)号：US20190314312A1

公开(公告)日：2019-10-17

申请号：US16316639

申请日：2017-07-11

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Ayelet EREZ ,  Noa STETTNER

IPC: A61K31/198 ,  A61K31/366 ,  A61P1/00 ,  A61P35/00

Abstract: Provided are uses of a therapeutically effective amount of citrulline for the manufacture of a medicament for treatment of a subject having an inflammatory bowel disease (IBD) and/or colon cancer. Also provided are pharmaceutical compositions comprising a therapeutic effective amount of citrulline and a therapeutically effective amount of a flavonoid for the treatment of an inflammatory bowel disease (IBD) and/or colon cancer and kits comprising same.

公开(公告)号：US10426821B2

公开(公告)日：2019-10-01

申请号：US15636683

申请日：2017-06-29

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irit Sagi ,  Eitan Wong ,  Ran Afik

IPC: C12N9/64 ,  A61K38/48

Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.

公开(公告)号：US10369172B2

公开(公告)日：2019-08-06

申请号：US14367917

申请日：2012-12-20

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair Reisner ,  Esther Bachar-Lustig

IPC: A61K35/28 ,  A61K35/17 ,  A61K35/22 ,  A61K35/38 ,  A61K35/39 ,  A61K35/407 ,  A61K35/42 ,  A61K31/675 ,  A61K35/34 ,  A61K35/36 ,  C12N5/00 ,  A61K31/198 ,  A61K31/255 ,  A61K31/7076 ,  A61K31/661 ,  A61K39/395 ,  A61K39/00 ,  A61K35/12

Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject; and subsequently (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per kilogram body weight, thereby treating the subject.

公开(公告)号：US20190195891A1

公开(公告)日：2019-06-27

申请号：US16325393

申请日：2017-08-18

Applicant: Yeda Research and Development Co. Ltd.

Inventor： David WALLACH ,  Andrew KOVALENKO ,  Seongmin YOON

IPC: G01N33/68 ,  C12Q1/48

CPC classification number: G01N33/6893 ,  A61K35/12 ,  A61K45/06 ,  C12Q1/485 ,  C12Q1/6883 ,  C12Q1/6888 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N2800/7095

Abstract: A method of detecting activation of a necroptosis activation pathway in a subject is disclosed. The method comprising: (a) obtaining a biological sample comprising exosomes from the subject; (b) detecting an activity or expression of a component of the necroptosis activation pathway in an exosome fraction of the biological sample, wherein an increase in the activity or expression of the component of the necroptosis activation pathway indicates the activation of said necroptosis activation pathway. Methods of diagnosing necroptosis or inflammation by determining the level of exosomes in a biological sample. Method of modulating endocytosis by inhibiting MLKL or a cell surface receptor and a pharmaceutical composition comprising a population of exosomes comprising a component of the necroptosis activation pathway and its use in therapy of diseases, such as inflammation and cancer.

公开(公告)号：US10329347B2

公开(公告)日：2019-06-25

申请号：US14827337

申请日：2015-08-17

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Idit Shachar ,  Inbal Binsky ,  Mirko Sobotta

IPC: G01N33/574 ,  C07K16/28 ,  C07K14/705 ,  C12Q1/6886 ,  A61K38/00

Abstract: A method of diagnosing B-CLL in a subject in need thereof is provided. The method comprising determining in a biological sample of the subject a level of CD84 isoform C (SEQ ID NO: 30), wherein an increase in the level of the CD84 isoform C (SEQ ID NO: 30) beyond a predetermined threshold with respect to a level of the CD84 in a biological sample from a healthy individual is indicative of the B-CLL.

公开(公告)号：US10314946B2

公开(公告)日：2019-06-11

申请号：US15890504

申请日：2018-02-07

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Jacob Klein ,  Ronit Goldberg ,  Noa Iuster ,  Raya Sorkin

IPC: A61L27/52 ,  A61L27/34 ,  A61K9/00 ,  C09D133/06 ,  A61L27/44 ,  C08F2/10 ,  C08F2/44

Abstract: Hydrogels and composite material containing hydrogels and liposomes dispersed therein, which exhibit a reduced friction coefficient compared to neat hydrogels or composites containing hydrogels, processes for preparing the same, and methods for using the same are disclosed.

公开(公告)号：US10294482B2

公开(公告)日：2019-05-21

申请号：US15312734

申请日：2015-05-21

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Ron Milo ,  Niv Antonovsky ,  Elad Noor ,  Arren Bar-Even ,  Yehudit Zohar ,  Lior Zelcbuch ,  Shmuel Gleizer ,  Shira Amram

IPC: C12N15/70 ,  C12N15/52 ,  C12N15/74 ,  C07K14/195 ,  C07K14/245 ,  C12N1/20 ,  C12N9/04 ,  C12N9/10 ,  C12N9/12 ,  C12N9/88 ,  C12N9/90

Abstract: A microorganism which is genetically modified so that it produces a first essential biomass precursor by metabolizing CO2 using a recombinant carbon fixation enzyme is disclosed. The microorganism produces a second biomass precursor by metabolizing an organic carbon source and not by metabolizing CO2. The microorganism does not use the organic carbon source for producing the first essential biomass precursor.

公开(公告)号：US10281459B2

公开(公告)日：2019-05-07

申请号：US14754785

申请日：2015-06-30

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： David Margulies ,  Leila Motiei ,  Zohar Pode

IPC: C07K7/06 ,  G01N33/58 ,  G01N33/53 ,  C07D417/06 ,  C07D417/14 ,  C07F9/6541 ,  G01N33/574 ,  G01N33/573 ,  C09K11/06

Abstract: The present invention is directed to fluorescent protein biosensors based on oligonucleotide cross reactive sensor arrays including a selective and a non-selective protein surface binding domain for protein detection. Interaction of different protein isoforms with the sensors of this invention yields a unique optical signature for each protein. The unique optical signature allows differentiating between closely related protein isoforms and diagnosing diseases and disorders associated with the proteins also in biofluids.

公开(公告)号：US20190091266A1

公开(公告)日：2019-03-28

申请号：US16198811

申请日：2018-11-22

Applicant: Yeda Research and Development Co., Ltd.

Inventor： Yair Reisner ,  Carmit Hillel-Karniel ,  Chava Rosen ,  Esther Bachar-Lustig ,  Elias Shezen

IPC: A61K35/42 ,  A61K35/28 ,  A61K9/00 ,  A61P11/00

Abstract: A method of treating a pulmonary disorder or injury in a subject in need thereof is disclosed. The method comprising administering to the subject non-syngeneic pulmonary tissue cells in suspension comprising an effective amount of hematopoietic precursor cells (HPCs) or supplemented with HPCs, wherein the effective amount is a sufficient amount to achieve tolerance to the pulmonary tissue cells in the absence of chronic immunosuppressive regimen. A method of inducing donor specific tolerance in a subject in need of a pulmonary cell or tissue transplantation is also disclosed.